



## Index

*Note:* Page numbers of article titles are in **bold face** type.

### A

- Acetaminophen, asthma prevalence and, 547–548
- Activity-induced asthma.  
*See* Exercise-induced asthma.
- Adenosine, in exercise-induced asthma, 704
- Adenovirus infections, as asthma triggers, 559–560
- Adrenal suppression, from corticosteroid therapy, 686
- Aerosols, inhalation of.  
*See* Inhaled medication.
- Age factors, in asthma, 525
- Air pollution, asthma and  
exercise-induced, 703–704  
in inner cities, 663–664  
indoor, 528  
outdoor, 528–529
- Airway hyperresponsiveness  
in asthma assessment, 598–599,  
606–607  
respiratory infection effects on, 568
- Albuterol  
for asthma, 583–586  
acute, 647–648  
efficacy of, 678–679  
exercise-induced, 706  
for wheezing, 647–648
- Allergy, asthma in  
in inner city children, 663  
respiratory infections interactions with,  
567–568
- Alternative medicine, for asthma, in inner cities, 668
- Anticholinergic agents, for asthma, 648–649
- Antihistamines, for exercise-induced asthma, 710
- Asthma  
activity-induced, **697–716**  
acute  
in respiratory infections, 560–561  
treatment of, 646–652  
assessment of, **595–610**  
activity-induced, 699–702  
newer methods for, 606–607  
nocturnal awakening rate in,  
603–605  
physical examination in, 601,  
700–701  
pulmonary function measures in,  
600–601  
questionnaires for, 701–702  
rescue inhaled beta-agonist use in,  
605–606  
severity classification, 596–597  
symptom monitoring in, 601–603  
classification of, 616–618, 636–638  
deficiency of, 612  
definition of, 535–535, 697  
education programs for, 669–670  
environmental exposures and, 662–665  
epidemiology of, 633–634, 677  
activity-induced, 697–699  
in inner cities, 657, 659  
international patterns in, **541–555**  
respiratory infections and,  
557–564  
ethnic differences in, 545–546,  
665–666, 668  
exacerbations of, reduction of,  
613–614  
fatal, 613, 615  
ethnic differences in, 665–666  
inhaled corticosteroid protection  
against, 680  
leukotriene antagonist protection  
against, 688  
geographical distribution of. *See* International Study of Asthma and Allergies in Children (ISAAC) program.  
in inner cities, **657–676**  
biologic vulnerability in, 665–666

- causes of, 659–660
  - environmental exposures and, 662–665
  - family characteristics in, 659, 661–662, 667–669
  - future work on, 672–673
  - interventions for, 669–672
  - outcomes of, 657–659
  - psychosocial stress and, 664
  - suboptimal management of, 666–669
  - infectious triggers of, **557–577**, 664–665
  - natural history of, **525–539**, 682
    - adult-onset, 533–534
    - factors modifying, 525–530
    - from childhood to adulthood, 531–533
    - in first six years, 530–531
    - initiation, 530–531
  - outcome of, in inner cities versus non-disadvantaged neighborhoods, 657–659
  - outgrowing of, 614–616
  - pathophysiology of
    - activity-induced, 703–704
    - respiratory infections and, 564–568
  - remission of, inhaled corticosteroids and, 681–683
  - severe
    - death in, 613, 615, 680, 688
    - in inner cities, 659
  - severity of, assessment of, 596–597
  - social work support for, 670
  - steroid-resistant, treatment of, 590
  - treatment of
    - activity-induced, 704–711
    - barriers to, 598–599
    - changing features of, 581–582
    - compliance with, 628–629
    - current approach to, 582–586
    - future of, 588–590
    - goals of, 595–596, 611–612, 628–629, 666, 678
    - home interventions for, 670–671
    - identification for, **579–593**, 613–619
    - in wheezing infants, **633–656**
    - inadequate, 580
    - indications for, 580–581
    - initiation of, 586
    - pharmacologic, **611–631**. *See also specific drugs.*
      - activity-induced, 704–711
      - adverse effects of, 683–687
      - combination, 581–582, 689–692, 709–710
      - evaluation of, 589–590
      - evidence-based, 618–619
      - history of, 581
      - identification for, 613–619
      - in inner cities, 666–667
      - inhaled. *See* Inhaled medication, for asthma.
      - patient identification for, 579–593
      - recommendations for, 619–627
      - tapering doses in, 628
      - therapeutic index of, 625
      - versus nontreatment, **677–695**
      - respiratory infections and, 569–570
      - school interventions for, 671–672
      - specialists in, 671
      - step-wise approach to, 636–638
      - steroid-resistant, 590
      - success of, barriers to, 598–600
      - versus nontreatment, **677–695**
- Atopy, asthma and, 525–526, 546
- ## B
- 
- Beclomethasone, inhaled, for asthma, 623–625, 684
  - Beta-agonists
    - for asthma
      - acute, 646–648
      - exercise-induced, 706–707
      - in combination therapy, 626–628, 689–690
      - inhaled, 605–606, 644–646
      - tapering of, 628
    - for wheezing, 646–648
  - Breath-enhanced jet nebulizers, 721
  - Bronchiolitis
    - as asthma trigger, 558–559
    - wheezing in, treatment of, 651
  - Bronchodilators, inhaled, for asthma, as rescue therapy, 605–606
  - Budesonide, inhaled
    - for asthma, 627, 638–642
      - acute, 650–651
      - clinical trials of, 582–586
      - efficacy of, 603, 678–680
      - exercise-induced, 705, 707–708, 710–711
      - growth effects of, 641–643, 684–685
      - in combination therapy, 689–691
      - in respiratory infections, 570
      - in young children, 586–587
      - morbidity and mortality impact of, 680–681
      - nocturnal awakening and, 604
      - osteoporosis from, 686
    - for wheezing, 638–642, 650–651

Candidiasis, from corticosteroid therapy, 686–687

Cataract, from corticosteroid therapy, 685–686

Chest pain, in exercise-induced asthma, 700

Childhood Asthma Management Program, 582–586, 599–600, 616

*Chlamydia pneumoniae* pneumonia, as asthma trigger, 559–560

Climate, asthma and, 549

Cockroach allergy, in inner city children, asthma and, 663

Common cold, as asthma trigger, 568

Corticosteroids  
inhaled  
for asthma, 638–643  
acute, 650–651  
administration methods for, 638–641  
adverse effects of, 683–687  
as first-line therapy, 680  
benefits of, 581–582  
clinical trials of, 582–586  
efficacy of, 598–599, 603, 678–680  
evidence-based recommendations for, 620–628  
exercise-induced, 704–705, 707–711  
growth effects of, 625, 641–643, 683–685  
in combination therapy, 626–628, 689–692  
in respiratory infections, 569–570  
in young children, 586–588  
indications for, 614  
morbidity and mortality impact of, 680–681  
natural history and, 529–530  
new developments in, 588–590  
nocturnal awakening and, 603–605  
preparations for, 678  
remission and, 681–683  
risks of, 625–626  
tapering of, 628  
for wheezing, 638–643, 650–651  
oral or parenteral  
for asthma, 569–570, 649–650  
for wheezing, in bronchiolitis, 569

Cromolyn  
for asthma, 623, 643, 706  
for wheezing, 643

Cultural factors, in asthma treatment, 668

Cytokines, in respiratory infections, asthma and, 567

---

## D

Dendritic cells, activation of, in respiratory infections, asthma and, 565–566

Depression, in caretakers, asthma management problems in, 669

Diet  
asthma prevalence and, 547  
for exercise-induced asthma, 711

Diffusion, in aerosol deposition, 719

Diskus inhaler, for dry powders, 725

Dry powder inhalers, for asthma, 724–726

Dysphonia, from corticosteroid therapy, 686–687

---

## E

Eczema, asthma with, 525, 546

Education, on asthma, 669–670

Endotoxin exposure, asthma and, in inner cities, 663–664

Environmental factors, in asthma, in inner cities, 662–665

Eosinophils, in asthma assessment, 606–607, 704

Epithelial cells, damage to, in respiratory infections, asthma and, 565

Ethnic factors, in asthma, 545–546, 665–666, 668

Eucapnic voluntary hyperpnea of dry air, in asthma, 702

Exercise-induced asthma, **697–716**  
definition of, 697  
diagnosis of, 699–702  
epidemiology of, 697–699  
pathophysiology of, 703–704  
treatment of, 704–711

---

## F

F protein, respiratory syncytial virus, asthma and, 566

Family characteristics, in inner-city asthma, 659, 661–662, 667–669

Fenoterol, for asthma, 651

Fluticasone, inhaled  
 for asthma, 615, 623, 625, 640–643  
 efficacy of, 603  
 exercise-induced, 705, 707–708  
 in combination therapy, 690  
 new developments in, 589  
 nocturnal awakening and, 604–605  
 for wheezing, 640–643

Food allergy, asthma with, 526

Forced expiratory volume in 1 second, in  
 asthma, 600  
 exercise-induced, 702  
 in inhaled medication trials, 583–586

Formoterol  
 for asthma, 581, 627  
 exercise-induced, 706–707  
 in combination therapy, 689–690  
 inhaled, 644–646  
 for wheezing, 644–646

Fractional exhaled concentration of nitric  
 oxide, in asthma, 606–607

## G

G protein, respiratory syncytial virus, asthma  
 and, 566

Gender, asthma natural history and, 527

Genetic factors, in asthma, 527–528, 545–546

Geographical distribution, of asthma. *See* Inter-  
 national Study of Asthma and Allergies  
 in Children (ISAAC) program.

Geometric standard deviation, of aerosol  
 particles, 718–719

Glaucoma, from corticosteroid therapy,  
 685–686

Global Initiative for Asthma  
 guidelines of, 612, 618, 625–626  
 treatment guidelines of, 582

Glucocorticoids. *See* Corticosteroids.

Granulocytes, activation of, in respiratory  
 infections, asthma and, 565–566

Gravitational sedimentation, in aerosol  
 deposition, 719

Gross domestic product, asthma prevalence  
 and, 548–549

Growth, corticosteroid therapy effects on, 625,  
 641–643, 683–685

## H

Health care facilities, in inner cities, asthma  
 treatment in, 666–667

Hydrocortisone, for asthma, 651

Hygiene hypothesis, for allergy and asthma  
 development, 563–564

Hypothalamic-pituitary-adrenal axis, cortico-  
 steroid therapy effects on, 684, 686

## I

Immune system, development of, infection  
 exposure in, 563–564

Immunization, rates of, asthma prevalence  
 and, 548

Inertial impaction, in aerosol deposition, 719

Infant(s), wheezing in. *See* Wheezing,  
 in infants.

Infections, respiratory.  
*See* Respiratory infections.

Inflammation, in asthma, 565–566

Inflammatory mediators, in exercise-induced  
 asthma, 703–704

Influenza  
 as asthma trigger, 558–559, 561  
 vaccine for, in asthma prevention, 570

Inhaled medication. *See also*  
 Corticosteroids, inhaled.  
 for asthma, 717–731  
 adverse effects of, 683–687  
 aerosol size and particle deposition,  
 718–720  
 benefits of, 581–582  
 clinical studies of, 582–586  
 dry powder inhalers for, 724–726  
 efficacy of, 598–599, 603,  
 678–680  
 evidence-based recommendations  
 for, 620–628  
 exercise-induced, 704–705,  
 707–711  
 high-dose, 587–588  
 history of, 717–718  
 in combination therapy, 689–692  
 in first-line therapy, 582–585, 680  
 in rescue therapy, 605–606  
 in young children, 586–588  
 indications for, 580–581, 614  
 morbidity and mortality impact of,  
 680–681  
 nebulizers for, 720–724  
 nocturnal awakening and, 603–605  
 pressurized meter dose inhalers for,  
 726–729  
 remission and, 681–683

Inner-city asthma. *See* Asthma, in inner cities.

Insurance, for inner city population, asthma treatment and, 666–667

Interferon- $\gamma$ , in respiratory infections, asthma and, 566

International Study of Asthma and Allergies in Children (ISAAC) program, 541–555

overview of, 542

phase one issues, 542–549

acetaminophen use, 547–548

children versus adults, 546

climate, 549

developed versus developing countries, 543–544

diet, 547

ecological studies, 546–549

English-speaking countries, 544–545

ethnic factors, 545–546

European northwest-to-southeast gradient, 545

genetic factors, 545–546

gross domestic product, 548–549

immunization, 548

known risk factors, 546

other atopic disorders, 546

tobacco use, 549

tuberculosis rates, 548

phase three issues, 552

phase two issues, 549–552

China, 551–552

Europe, 550–551

Scandinavia, 551

Ipratropium bromide, for asthma, 648–649, 651

ISAAC program. *See* International Study of Asthma and Allergies in Children (ISAAC) program.

## J

Jet nebulizers, for asthma, 720–721, 723

## L

Leukotriene antagonists

for asthma, 581, 623–624, 627, 643–644

efficacy of, 687

exercise-induced, 705, 709

in young children, 586

preparations for, 687

safety of, 688

for wheezing, 569, 643–644

Levalbuterol, for asthma, 581

Loratadine, for exercise-induced asthma, 710

Lymphocytes, recruitment of, in respiratory infections, asthma and, 566

## M

Macrophages, activation of, in respiratory infections, asthma and, 565–566

Mask, for nebulizer therapy, 721–722

Mass median aerodynamic diameter, of aerosol particles, 718–719

Maxair Autoinhaler, for asthma drug delivery, 729

Metapneumovirus infections, as asthma triggers, 558–559

Meter dose inhalers, pressurized, 726–729

Methacholine challenge test, in asthma, 606–607, 702

Methylprednisolone, for asthma, short-course, 649–650

Monocytes, activation of, in respiratory infections, asthma and, 565–566

Montelukast

for asthma, 581, 623–624, 643–644

efficacy of, 687

exercise-induced, 705, 709–711

in combination therapy, 691

in young children, 586

for wheezing, 569, 643–644

*Mycoplasma pneumoniae* pneumonia, as asthma trigger, 559–560

## N

National Asthma Education and Prevention Program, guidelines of, 612–627

National Heart, Lung, and Blood Institute asthma assessment guidelines of, 596–597

asthma treatment guidelines of, 582–586

Nebulizers, for asthma, 720–724

Nedocromil

for asthma, 582–586, 643, 706

for wheezing, 643

Neutrophilia, in respiratory infections, asthma and, 566

Nitric oxide

fractional exhaled concentration of, in asthma, 606–607

in exercise-induced asthma, 704

**O**

- Osmotic hypothesis, of exercise-induced asthma, 703
- Osteoporosis, from corticosteroid therapy, 685

**P**

- Parainfluenza virus infections, as asthma triggers, 558–559
- Peak flow monitoring, in asthma, 600–601
- Physical training, for exercise-induced asthma, 705–706
- Pneumonia, as asthma trigger, 559–560
- Poverty, asthma and. *See* Asthma, in inner cities.
- Pranlukast, for asthma, 627, 690–691
- Prednisolone, for asthma, short-course, 649
- Prednisone
  - for asthma, 583–586
    - osteoporosis from, 686
    - short-course, 650
  - for wheezing, in infants, in bronchiolitis, 569
- Pressurized meter dose inhalers, 726–729
- Prostaglandins, in exercise-induced asthma, 704
- Psychosocial factors, in asthma, in inner cities, 664
- Pulmonary function tests, in asthma, 583–586, 600–601

**R**

- Respiratory infections, as asthma triggers, 529, 557–577
  - acute exacerbations, 560–561
  - airway hyperresponsiveness in, 568
  - allergy effects on, 567–568
  - bronchiolitis, 558–559
  - chronic, 559–560
  - common cold, 568
  - epidemiology of, 557–564
  - hygiene hypothesis and, 563–564
  - in inner cities, 664–665
  - inflammation in, 565–566
  - influenza, 558–559, 561
  - pathophysiology of, 564–568
  - respiratory syncytial virus, 558–559, 566
  - rhinovirus, 560–561, 564–568
  - sinusitis, 561–563

treatment related to, 569–570

viral, 560–561

- Respiratory syncytial virus infections, as asthma triggers, 558–559, 566
- Rhinoconjunctivitis, allergic, asthma and, 546
- Rhinovirus infections, as asthma triggers, 560–561, 564–568
- RNA, double-stranded, replication of, in respiratory infections, asthma and, 565
- Roflumilast, for asthma, 711
- Rules of Two, for asthma treatment, 613

**S**

- Salbutamol. *See* Albuterol.
- Salmeterol
  - for asthma, 581, 615, 622, 627
  - efficacy of, 679
  - exercise-induced, 706–707, 709–710
  - growth effects of, 684
  - in combination therapy, 689–690
  - inhaled, 644–646
  - for wheezing, 644–646
- School, asthma management in education programs in, 669
- interventions in, 671–672
- Sinusitis, as asthma trigger, 561–563
- Sleep, awakening during, in asthma, 603–605
- Smoking, exposure to, asthma in, 526–527, 549, 662
- Social support, for asthma, 670
- Sodium chloride, dietary restriction of, for exercise-induced asthma, 711
- Spirometry, in asthma, 600
- Strachan hygiene hypothesis, for allergy and asthma development, 563–564
- Stress, in asthma, in inner cities, 664

**T**

- Terbutaline, for asthma, 707
- Terfenadine, for asthma, 710
- Theophylline
  - for asthma, 627, 646
    - acute, 651–652
    - growth effects of, 684
  - for wheezing, 646

Thermal hypothesis, of exercise-induced asthma, 703

Thrush, from corticosteroid therapy, 686–687

Triggers, of asthma  
  exercise, **697–716**  
  respiratory infections, **557–577**

Tuberculosis, asthma prevalence and, 548

Turbuhaler, for dry powders, 724–725

---

**U**

Ultrasonic nebulizers, for asthma, 720

---

**V**

Vaccine, influenza, in asthma prevention, 570

Venturi type jet nebulizers, for asthma, 720

Vibrating mesh technology, for nebulizers, 723

Vocal cord dysfunction, versus exercise-induced asthma, 701

---

**W**

Wheezing  
  in allergy, pathophysiology of, 567–568  
  in asthma  
    adult-onset of, 533–534

  natural history of, 531–533  
  persistent, 530–531  
  transient, 530–531

in infants, **633–656**  
  differential diagnosis of, 634  
  natural history of, 634–635  
  treatment of  
    controller, 636–646  
    in acute episodes, 646–652  
    in bronchiolitis, 569  
    indications for, 635–636  
    without definite diagnosis, 633–634

in respiratory infections  
  chronic, 559–560  
  pathophysiology of, 564–568  
  respiratory syncytial virus, 558–559, 566  
  viral, 560–561

---

**Z**

Zafirlukast  
  for asthma, 623, 627, 643  
  efficacy of, 688  
  exercise-induced, 709–710  
  safety of, 688  
  for wheezing, 643

Zileuton, for asthma, 710